Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Jazz Pharma Plc (JAZZ)

Jazz Pharma Plc (JAZZ)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Jazz Pharma Plc FIFTH FLOOR WATERLOO EXCHANGE WATERLOO ROAD DUBLIN L2 D04 IRL

P: 011-353-1634 F: 353-163-4785

Description:

Jazz Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on identifying, developing and commercializing innovative products to meet unmet medical needs in neurology and psychiatry. Company's goal is to build a broad portfolio of products through a combination of internal development and acquisition/in-licensing activities and to utilize our specialty sales force to promote products in our target markets. They apply novel formulations and drug delivery technologies to known drug compounds, and compounds with the same mechanism of action or similar chemical structure as marketed products, to improve patient care by improving efficacy, reducing adverse side effects or increasing patient compliance relative to existing therapies. Based in Palo Alto, California, the company is committed to working closely with patients, patient advocacy groups and healthcare professionals.

Key Statistics

Overview:

Market Capitalization, $K 7,362,411
Shares Outstanding, K 56,573
Annual Sales, $ 1,891 M
Annual Net Income, $ 447,100 K
Last Quarter Sales, $ 534,130 K
Last Quarter Net Income, $ 261,900 K
60-Month Beta 1.09
% of Insider Shareholders 4.30%
% of Institutional Shareholders 87.71%
Float, K 54,140
% Float 95.70%

Growth:

1-Year Return -10.09%
3-Year Return 15.06%
5-Year Return -25.45%
5-Year Revenue Growth 116.74%
5-Year Earnings Growth 119.75%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings 4.10 on 11/05/19
Next Earnings Date N/A
Earnings Per Share ttm 13.42
EPS Growth vs. Prev Qtr 0.00%
EPS Growth vs. Prev Year 13.00%
Annual Dividend Rate, $ 0.00
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00

JAZZ Ratios

Ratio
Price/Earnings ttm 9.10
Price/Earnings forward 14.25
Price/Earnings to Growth 0.99
Return-on-Equity (After Tax) 27.99
Return-on-Assets (Before Tax) 15.01
Profit Margin % 23.64
Net Margin % 43.42
Debt/Equity 0.58
Price/Sales 3.77
Price/Cash Flow 7.52
Price/Book 2.34
Book Value/Share 52.67
Interest Coverage 7.87
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar